Published in PLoS One on August 29, 2014
A top-down view of the tumor microenvironment: structure, cells and signaling. Front Cell Dev Biol (2015) 0.81
Identification of the miRNA-mRNA regulatory network of small cell osteosarcoma based on RNA-seq. Oncotarget (2017) 0.77
Oxidored-nitro domain-containing protein 1 expression is associated with the progression of hepatocellular carcinoma. Oncol Lett (2016) 0.76
Protein phosphatase 2A regulation of markers of extracellular matrix remodelling in hepatocellular carcinoma cells: functional consequences for tumour invasion. Br J Pharmacol (2017) 0.75
SESN2 correlates with advantageous prognosis in hepatocellular carcinoma. Diagn Pathol (2017) 0.75
Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma. Sci Rep (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 12.29
miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell (2009) 4.48
The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta (2010) 3.33
Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol (2010) 2.75
TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene (2009) 2.33
Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat (2009) 2.18
Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer (2008) 1.89
The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer (2014) 1.65
Ethnic disparities and liver transplantation rates in hepatocellular carcinoma patients in the recent era: results from the Surveillance, Epidemiology, and End Results registry. Liver Transpl (2014) 1.56
MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res (2010) 1.51
Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res (2008) 1.24
Comparison between the fifth and sixth editions of the AJCC/UICC TNM staging systems for hepatocellular carcinoma: multicentric study on 393 cirrhotic resected patients. Eur J Surg Oncol (2005) 1.08
Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression. Br J Cancer (2010) 1.06
Alpha B-crystallin is a new prognostic marker for laryngeal squamous cell carcinoma. J Exp Clin Cancer Res (2012) 1.05
Multiple interactive factors in hepatocarcinogenesis. Cancer Lett (2013) 1.04
Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res (2006) 1.01
Enhanced metastatic dissemination to multiple organs by melanoma and lymphoma cells in timp-3-/- mice. Oncogene (2006) 1.00
Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix metalloproteinase 2-down-regulated lung cancer. Cancer Res (2008) 0.99
Accumulation of the mutations in basal core promoter of hepatitis B virus subgenotype C1 increase the risk of hepatocellular carcinoma in Southern China. Int J Clin Exp Pathol (2013) 0.99
Promoter methylation and expression of TIMP3 gene in gastric cancer. Diagn Pathol (2013) 0.98
Loss of TIMP-3 promotes tumor invasion via elevated IL-6 production and predicts poor survival and relapse in HPV-infected non-small cell lung cancer. Am J Pathol (2012) 0.96
Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in Qidong, China. PLoS One (2014) 0.95
Tissue inhibitor of metalloproteinases-3 interacts with angiotensin II type 2 receptor and additively inhibits angiogenesis. Cardiovasc Res (2008) 0.95
Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia. Mol Cancer (2009) 0.93
High expression of inositol polyphosphate phosphatase-like 1 associates with unfavorable survival in hepatocellular carcinoma. Int J Clin Exp Pathol (2013) 0.93
Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only. Oncol Rep (2009) 0.93
Elevated expression of SHIP2 correlates with poor prognosis in non-small cell lung cancer. Int J Clin Exp Pathol (2013) 0.90
Inhibition of tumor growth and induction of apoptosis in prostate cancer cell lines by overexpression of tissue inhibitor of matrix metalloproteinase-3. Cancer Gene Ther (2009) 0.88
Quantitative detection of TIMP-3 promoter hypermethylation and its prognostic significance in esophageal squamous cell carcinoma. Oncol Rep (2008) 0.88
Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells. Cancer Gene Ther (2012) 0.88
Multivalent pseudopeptides targeting cell surface nucleoproteins inhibit cancer cell invasion through tissue inhibitor of metalloproteinases 3 (TIMP-3) release. J Biol Chem (2012) 0.87
TIMP-3 gene transfection suppresses invasive and metastatic capacity of human hepatocarcinoma cell line HCC-7721. Hepatobiliary Pancreat Dis Int (2007) 0.87
Genetic polymorphisms at TIMP3 are associated with survival of adenocarcinoma of the gastroesophageal junction. PLoS One (2013) 0.86
TIMP-3 promotes apoptosis in nonadherent small cell lung carcinoma cells lacking functional death receptor pathway. Int J Cancer (2011) 0.86
Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer. J Surg Oncol (2007) 0.85
Expression of ADAMTS-1, ADAMTS-4, ADAMTS-5 and TIMP3 by hepatocellular carcinoma cell lines. Int J Oncol (2012) 0.81
EZH2 regulates cancer cell migration through repressing TIMP-3 in non-small cell lung cancer. Med Oncol (2013) 0.81
Integrin α7 binds tissue inhibitor of metalloproteinase 3 to suppress growth of prostate cancer cells. Am J Pathol (2013) 0.80
Adenovirus carrying TIMP-3: a potential tool for cervical cancer treatment. Gynecol Oncol (2007) 0.79
A peptide derived from TIMP-3 inhibits multiple angiogenic growth factor receptors and tumour growth and inflammatory arthritis in mice. Angiogenesis (2013) 0.79
Expression of MMP-3 and TIMP-3 in gastric cancer tissue and its clinical significance. Oncol Lett (2011) 0.77